MedInnovation has developed a new diagnostic platform called Albumin Functionality Test (AFT). The platform allows to detect a number of severe diseases like cancer, liver disorders (cirrhosis) and sepsis at the early stage. AFT is based on Electron Spin Resonance Spectroscopy technique providing physicians with a fast, non-invasive and reliableroutine laboratory blood test. AFT is the only test to determine the functional characteristics of human serum albumin (HSA) - main transport protein in the blood system. The platform allows to obtain 45 independent biophysical parameters of albumin for further analyses. It opens a great perspective for AFT as a potential backbone diagnostic technology. MedInnovation has competed development of full set of instruments including digital ESR-Analyzer, Automated Liquid Handling System, Software, Data Base and Reagent Kits. Having promising results from a number of POC and phase II clinical trials the company is on the way to validate the test in the US and Europe. Medinnovation is TÜV-certified producer of medical devices according to DIN EN 13485:2016

Biotechnology

Health Diagnostics

MedInnovation

MedInnovation's headquarters in Berlin, Germany

Description

People (2)

Konstantin C.

Eugen Levonyuk

Jobs